NovoCure Limited
NVCR
$15.23
$0.030.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.60% | 12.30% | 8.11% | 7.81% | 5.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.60% | 12.30% | 8.11% | 7.81% | 5.62% |
| Cost of Revenue | -0.88% | 1.06% | 24.61% | 26.45% | 19.67% |
| Gross Profit | 21.43% | 16.01% | 3.96% | 2.30% | 1.41% |
| SG&A Expenses | 0.57% | 46.76% | -20.28% | 4.54% | 7.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.11% | 26.72% | -4.55% | 8.57% | 7.82% |
| Operating Income | 73.27% | -89.57% | 38.38% | -12.24% | -17.69% |
| Income Before Tax | 64.40% | -128.61% | 25.82% | -39.09% | -53.90% |
| Income Tax Expenses | -37.87% | -53.28% | -253.56% | -19.33% | -51.53% |
| Earnings from Continuing Operations | 60.99% | -107.28% | 62.84% | -21.92% | -20.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.99% | -107.28% | 62.84% | -21.92% | -20.27% |
| EBIT | 73.27% | -89.57% | 38.38% | -12.24% | -17.69% |
| EBITDA | 82.66% | -96.33% | 41.17% | -9.19% | -17.43% |
| EPS Basic | 62.48% | -100.26% | 64.08% | -17.92% | -16.10% |
| Normalized Basic EPS | 65.75% | -138.94% | 22.42% | -34.59% | -41.44% |
| EPS Diluted | 62.50% | -100.26% | 64.08% | -17.92% | -16.17% |
| Normalized Diluted EPS | 65.75% | -138.94% | 22.42% | -34.59% | -41.44% |
| Average Basic Shares Outstanding | 3.98% | 3.51% | 3.47% | 3.38% | 3.60% |
| Average Diluted Shares Outstanding | 3.98% | 3.51% | 3.47% | 3.38% | 3.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |